education specific for MG (see Table 1 ). When severe, MG can affect respiratory muscles, including diaphragmatic muscles, and the patient may require respiratory support either in an intensive care setting or non-invasive ventilation (for example, bilevel positive airway pressure). An MG crisis implies a deterioration of bulbar and/or respiratory muscles such that the patient requires feeding via a nasogastric tube, often with intubation and mechanical ventilation requiring management in an intensive care unit.
Pathogenesis
What causes MG is unknown. Presumed culprits include a genetic predisposition to autoimmunity (including gender) and some infections. Early-onset AChR antibody-positive MG is associated with particular human leucocyte antigens (HLA), including DRB1*03, DQA1*0501, DQB1*0201. The thymus gland is important in MG immunogenesis as it has the full immunological repertoire to mount an immune response to the nicotinic AChR. The thymus gland in AChR-antibody-positive MG is hyperplastic in about 85% of cases and harbours thymoma in a further 10%. The remaining MG patients, especially those with late-onset MG, have thymic atrophy.
Antibodies in myasthenia
Patients with purely ocular MG have detectable AChR antibodies in about 50% of cases. In contrast, AChR antibodies are present in about 80% of patients with generalised MG. The remaining patients are referred to as 'seronegative'. In this subgroup, around 50% have antibodies to muscle-specific tyrosine kinase (MuSK). MuSK is a protein located at the post-synaptic membrane, which is responsible for clustering of the AChR at the muscle membrane surface. MuSK-MG can be indistinguishable from AChR-MG, but, in some cases, patients can present with predominantly bulbar muscle weakness and some patients may be refractory to conventional treatments. Of the remaining generalised MG patients without detectable antibodies, a proportion harbour low-affinity AChR antibodies. These can be detected in a newly described cell-based assay, which is not yet commercially available.
Investigations for myasthenia
If MG is suspected, the patient's serum should be tested for AChR antibodies. If these are negative, then MuSK antibodies should also be tested, even if only ocular symptoms are present.
Neurophysiological testing should be performed to confirm the diagnosis of MG, especially if antibodies are undetectable or testing not available. In MG, repetitive nerve stimulation (RNS) studies show a significant decremental response (>9%) between the first compound muscle action potential (CMAP) and the fourth or fifth CMAP when the nerve to an affected muscle is stimulated (Figure 2 ). Nerves commonly tested include the ulnar, radial, accessory and/or facial nerves. While specific for MG, there are a number of technical issues with RNS which can result in false positives and false negatives.
Single-fibre electromyography (SFEMG) is a more sensitive test, in which adjacent single muscle fibres are analysed to determine how time-locked their responses are with respect to each other. With significant neuromuscular junction instability, the time taken for the nerve action potential to cross the NMJ becomes variable, generating increased 'jitter' (Figure 3) . With profound weakness, impulse blocking can be detected. Single-fibre electromyography can also be abnormal in other conditions (e.g. radiculopathy, motor neurone disease or mitochondrial myopathy). The Tensilon test is a bedside test in which edrophonium, a short-acting acetylcholinesterase inhibitor, is administered intravenously. The aim of the test is to demonstrate reversibility of muscle weakness. The test should only be performed if unequivocal weakness can be demonstrated (for example, ptosis) and it should be performed double-blind and placebo-controlled. There is a risk, especially in the elderly, of inducing significant bradycardia and cardiac arrest on administering intravenous edrophonium, so a cardiac arrest trolley should be kept close at hand. For this reason, many physicians administer atropine prophylactically.
Imaging of the thorax (computed tomography or magnetic resonance imaging) should be performed in all MG patients, irrespective of antibody status, to exclude the presence of an anterior mediastinal mass, which could represent thymic hyperplasia or thymoma.
Treatment
For mild MG, symptomatic treatment with pyridostigmine, an acetylcholinesterase inhibitor, is often sufficient. Pyridostigmine makes more acetylcholine available to the intact AChRs and thereby improves muscle strength. Its therapeutic potential is limited and the half-life means that it wears off after 5-6 hours. For patients who do not respond adequately to pyridostigmine, immunosuppression is important to induce remission. This usually involves a combination of corticosteroids and a steroid-sparing agent (commonly azathioprine Myasthenia gravis crisis should be treated in an intensive care unit, especially when mechanical ventilation is required. Myasthenia gravis status is improved rapidly using plasmapheresis (usually five exchanges) or intravenous immunoglobulin (a five-day course prescribed at 0.4 g/kg/day). In some refractory cases, in which immunosuppression is inadequate, remission can be achieved and maintained by repeated treatment with immunoglobulin or plasmapheresis.
Thymectomy is indicated in all patients with evidence of anterior mediastinal mass on thoracic imaging and also in patients with AChR antibody-positive generalised MG who are 50 years or younger and whose symptoms have been ongoing for two years or less. This is not evidencebased, however, and it is still uncertain whether the duration of MG symptoms should influence the decision for thymectomy. The ongoing international thymectomy trial should help us further with deciding who are the right candidates for thymectomy. It is not clear whether patients with thymic atrophy also benefit from thymectomy and the trial may help us to answer this, too. In patients with malignant thymoma, additional therapy in the form of radiotherapy or chemotherapy may be indicated.
Myasthenia gravis triggers
Physical or emotional stress can trigger or exacerbate MG, as can significant infections. Surgery could be considered as an example of physical stress to the body. If the patient is already established on treatment, then a small increase in dosage of pyridostigmine and/or steroids may be indicated, but this should be tailored according to the individual patient and their circumstances.
The first trimester of pregnancy may also cause a flareup of MG symptoms, but MG status tends to improve during the second and third trimester. Fatigue becomes prominent as the pregnancy advances. 
Prognosis
Ocular MG is relatively benign but still disabling if ophthalmoparesis is refractory to treatment. Childhoodonset MG bears a good prognosis, with the majority going into spontaneous remission. Myasthenia gravis associated with thymoma can be more difficult to treat and patients are more vulnerable to relapse. Because most patients are commenced on immunosuppression at disease presentation, it is difficult to ascertain the rate of spontaneous remission in the adult population, but this is thought to stand around 10%. The majority of patients will achieve significant stabilisation of MG status with minimal manifestations and only a minority will be refractory to treatment. Predominant bulbar presentations obviously carry higher morbidity and mortality risks especially in the elderly. The overall mortality rate in MG is 3-5%.
laMBert-eaton MyasthenIc syndroMe
Lambert-Eaton myasthenic syndrome (LEMS) is an acquired immune-mediated condition, associated in 90% of cases with antibodies to the voltage-gated calcium channels (VGCCs) on the pre-synaptic nerve terminal. The VGCC is crucial in allowing calcium entry into the nerve terminal and thereby facilitating the release of acetylcholine vesicles.
The clinical presentation of LEMS is different from that of MG. Lower limb muscle weakness is more prominent as an initial symptom, and weakness affecting upper limbs, face, and ocular muscles occurs later. Autonomic features, such as dry mouth, dry eyes and sphincter dysfunction, may be present. The typical waddling gait of patients with LEMS is due to a combination of proximal lower limb weakness and the fact that VGCC antibodies also attack receptors on cerebellar granule cells, resulting in central ataxia. The reflexes in LEMS patients are significantly reduced or absent but will often return after exercise. This is known as potentiation of the reflex. Lambert-Eaton myasthenic syndrome can be seen as a paraneoplastic syndrome, often associated with small cell lung cancer.
A search for underlying malignancy should take place in all patients presenting with LEMS and continue for the Symptomatic treatment in LEMS consists of 3,4-diaminopyridine (3,4-DAP), which blocks voltage-gated potassium channels, prolonging the nerve action potential and thus enhancing calcium entry. Pyridostigmine may also help. The immunosuppression strategy is essentially the same as in MG, but with caution in paraneoplastic LEMS, and intravenous immunoglobulin or plasmapheresis may also be useful.
congenItal MyasthenIc syndroMes
Congenital myasthenic syndromes are extremely rare (about five cases per million in the uK) inherited forms of myasthenic syndromes. Most, but not all, present with muscle weakness from birth. They are often a result of mutations affecting one of the AChR subunits (commonly the epsilon subunit), but mutations affecting other proteins at the post-synaptic membrane such as rapsyn (a cytoplasmic membrane-associated protein associated with the intracellular portion of AChRs and crucial in the AChR clustering process) and DOK-7 (downstream of kinase, important in formation of AChR clusters and of the neuromuscular synapse) are almost as common (Figure 1 ).
Treatment with immunosuppression is not indicated in these cases. The phenotype varies depending on the specific mutation. Most but not all patients with congenital myasthenic syndrome benefit from treatment with 3,4-DAP or pyridostigmine. Ephedrine and/or salbutamol are also effective in syndromes associated with DOK-7 mutations. Patients with slow channel syndromes (the only autosomal dominantly inherited congenital myasthenic syndrome in which AChR channel opening is prolonged) usually respond to fluoxetine or quinidine. 
